The Preclinical Library

BPC-157 is a fifteen-amino-acid sequence derived from a larger gastric protein, examined almost entirely in rodent models by a research lineage concentrated in Zagreb. The published record spans tendon transection, muscle crush, colitis, and various chemically induced injury models in rats and mice, and it is unusually broad for a compound that has passed through so few independent hands.

Reported observations in these models include accelerated closure of tendon defects and improved histological scores in injured gut. What the literature rarely provides is what a skeptical reader needs first: blinded outcome assessment, preregistered endpoints, and confirmation by laboratories with no connection to the originating group. Nearly every positive report shares authorship lineage, which means the record demonstrates productivity more clearly than it demonstrates replication.

Mechanistic proposals — growth-factor pathway modulation, nitric-oxide system involvement — remain hypotheses generated within the same lineage. None of this makes the observations false. It makes them, at present, model-specific and lineage-confined, and BENCHLINE reports them that way.

Thymosin β4 is an abundant intracellular peptide best characterized as an actin-sequestering molecule. Its preclinical literature covers dermal wound models in rodents, cardiac injury models in mice, and corneal models, with reported observations including altered cell migration and reduced inflammatory cell infiltrate in injured tissue.

The record is more institutionally distributed than the BPC-157 literature, but it is fragmented: models differ in species, injury type, and endpoint timing, which makes the studies difficult to line up side by side. A reader counting papers will overestimate what has been shown; a reader counting comparable experiments will find far fewer.

TB-500, the name under which fragments of the sequence circulate commercially, appears rarely in the peer-reviewed record itself. BENCHLINE covers the published preclinical work on the parent peptide and its studied fragments; it does not cover products, sources, or use.

GHK-Cu is a copper-binding tripeptide studied since the 1970s, primarily in cultured human dermal fibroblasts, rodent wound models, and — extensively — in research adjacent to the cosmetics industry. Reported in-vitro observations include altered expression of matrix-related genes and increased collagen synthesis markers in fibroblast cultures.

The distance between a gene-expression change in a culture dish and a tissue-level claim is precisely the distance this publication exists to measure. Fibroblast cultures are not skin; skin in a rodent wound model is not human skin in ordinary life. Much of the GHK-Cu record sits upstream of even those comparisons, and a meaningful share of it carries commercial sponsorship that the methods sections do not always make prominent.

The literature is useful as an example of how a plausible mechanism — copper delivery, matrix signaling — can accumulate a large citation count without ever being tested against the question readers actually bring to it.

KPV is the three-amino-acid terminal fragment of α-MSH, examined chiefly in murine models of intestinal inflammation — DSS-induced colitis being the most common — and in cultured intestinal epithelial cells. Reported observations include reduced inflammatory cytokine readouts and improved histological colitis scores in treated animals.

The colitis literature as a whole carries known constraints: DSS models reproduce some features of human inflammatory bowel disease and miss others, and a compound can shift a histology score in a mouse colon while remaining silent in every human context. The KPV record is coherent within those models, modest in scale, and largely confined to a small number of research groups.

Cell-culture experiments — epithelial monolayers exposed to inflammatory stimuli — provide mechanistic texture but cannot stand in for intact tissue. BENCHLINE treats the in-vitro and in-vivo records here as two separate bodies of evidence that happen to share a molecule.

LL-37 is the only cathelicidin found in humans, and its preclinical literature is the most mechanistically diverse in this Library: antimicrobial assays against bacterial and fungal cultures, biofilm disruption experiments, murine wound and infection models, and a substantial immunology literature describing effects on immune-cell signaling.

That diversity is a double edge. LL-37 interacts with membranes nonspecifically, which means in-vitro readouts are sensitive to concentration, medium composition, and assay format; results that look consistent at the level of titles often are not consistent at the level of methods. Readers should also note the publication imbalance toward antimicrobial activity, since immunomodulatory findings are harder to reproduce across assay systems.

Independent replication exists here in a way it does not for several other entries in this Library — many groups, many systems — but replication of an observation about a molecule in a defined assay is a different thing from evidence about tissue, disease, or therapy, and the record remains preclinical.

Thymosin α-1 occupies an unusual position in this Library: it is the one entry with a genuine clinical trial history in some jurisdictions, yet the bulk of its literature remains preclinical — murine models of infection and immune suppression, and cultured immune-cell systems examining T-cell and dendritic-cell markers.

The preclinical record describes immunological readouts: cell-surface markers, cytokine profiles, pathogen clearance in animal infection models. These are real measurements in real models, and they are also several inferential steps away from the clinical questions the peptide is most often asked about. Regulatory status differs by country and says nothing by itself about the strength of the underlying evidence for any particular use.

BENCHLINE's coverage stays at the bench: what the animal and cell studies measured, under what conditions, and how consistently those measurements recur across independent laboratories.

MOTS-c belongs to the young literature of mitochondrial-derived peptides — small sequences encoded within the mitochondrial genome itself. The first MOTS-c report appeared in 2015, which means this is a literature without deep roots: most of what is published has been published recently, by a limited number of groups, in rodent metabolic models and cultured muscle cells.

Reported observations include altered glucose handling in high-fat-diet mouse models and changes in exercise-capacity readouts in aged mice, alongside proposed mechanisms involving folate metabolism and AMPK-associated signaling. These are interesting, hypothesis-generating results from a young field, and they are also exactly the conditions under which early literatures most often overstate themselves.

The honest summary is short: MOTS-c has a coherent mechanistic story, a thin replication base, and no established human relevance. BENCHLINE covers it as an example of how to read a literature that is still being written.

Humanin was identified in 2001 in a screen for factors protecting cultured neurons from insults modeled on familial Alzheimer's disease. Its literature has since broadened into rodent models of neuronal injury, metabolic disease, and cardiovascular stress, with reported observations centered on cell-survival signaling.

The neuroscience entries in this Library sit at the far end of the translation problem. Cultured neurons are not a brain; a rodent model of a human neurodegenerative disease is a partial analogy, not a rehearsal. The Humanin record is mechanistically respectable — receptor proposals, signaling pathways, dose-dependent cell-survival curves — and it remains preclinical throughout.

As with MOTS-c, the mitochondrial-derived framing has attracted summary-writing that runs ahead of the experiments. BENCHLINE's profile stops where the evidence stops.